-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (01276) obtained a notice of approval for drug clinical trials

Zhitongcaijing·12/29/2025 09:57:07
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue SHR-4375 injections, adbelizumab injections, SHR-8068 injections, bevacizumab injections, HRS-4642 injections, SHR-9839 for injections (sc)'s “Drug Clinical Trial Approval Notice” will conduct clinical trials in the near future.